QuesGen Systems, a provider of research services to organizations and scientists working on brain health and treatments for traumatic brain injury (TBI), is expanding its business and has announced the establishment of a new business relationship with ImmunArray, a private diagnostics company with headquarters in Rehovot, Israel, and Richmond, Virginia.
ImmunArray is a company dedicated to the development of investigational blood-based tests that help the diagnosis and management of complex acute and chronic immune and neurodegenerative diseases. So far, the company has developed and released the first of a set of products directed at diagnosis and management of systemic lupus erythematosus (SLE), called the SLE-key Rule-Out Test and is now working on new sets of TBI biomarkers.
ImmunArray will use the QuesGen platform to support the development of these next-gen, biomarker-based diagnosis and monitoring for autoimmune disease and TBI, with research currently being developed in collaboration with leading medical centers in the U.S. and Israel.
“This new relationship with QuesGen Systems is an important milestone for ImmunArray, particularly at a time when we are expanding both our revenues and investment base,” Donna Edmonds, ImmunArray’s CEO and chairman of the board, said in a press release.
“QuesGen’s expansive database and analytic capabilities will not only help us validate our work from a quantitative standpoint in lupus, especially as we contemplate expanded studies and a registry, but also further enhance our data management and analysis capabilities as we broaden our study populations and clinical data collection in both lupus and TBI populations. We look forward to tapping QuesGen’s expertise and resources,” Edmonds said.
SLE is a chronic autoimmune disease that is especially difficult to diagnose due to the heterogeneity of clinical manifestations and genetic profiles observed in patients so far. The most common symptoms include joint pain, skin rash, and fever. Many patients experience sudden flareups of SLE, in which symptoms worsen rapidly and then settle down. The diagnosis of SLE is based on symptom history and antinuclear antibodies blood test results. The diversity in SLE contributes to the limited success of clinical trials that have been designed and developed so far.